Brian Piekos - Feb 21, 2025 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
Chief Financial Officer
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Stock symbol
KALV
Transactions as of
Feb 21, 2025
Transactions value $
$0
Form type
4
Date filed
2/25/2025, 08:35 PM
Previous filing
Sep 11, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Restricted Stock Unit Award $0 +80K $0.00 80K Feb 21, 2025 Common Stock 80K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2 3/16th of the total number of shares underlying the RSUs shall vest on November 21, 2024 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate.